Integra LifeSciences Holdings Corporation (IART) — Fair Value Analysis
Base-case fair value (P50): $15.19 · Current price: $13.92 · Verdict: Fairly Valued
The Verdict on IART
INTEGRA LIFESCIENCES HOLDINGS CORP (IART) currently trades at $13.92, and our Monte Carlo simulations indicate it is Fairly Valued. The median fair value (P50) for IART is calculated at $15.19, suggesting a potential upside of +9.1% from its current trading level. This assessment, derived from thousands of forward-looking scenarios, places IART in a balanced risk-reward profile. Despite the positive gap to the $15.19 median, the magnitude does not suggest a significant undervaluation, rather aligning the current $13.92 market price closely with its intrinsic worth as determined by our rigorous models.
How IART stacks up against peers
In terms of fundamental health, IART is categorized with an average quality tier. This rating reflects its operational and financial health when benchmarked against its sector peers, suggesting neither significant outperformance nor underperformance on key metrics. The current trading price of $13.92 thus reflects a company that, while having a +9.1% potential to its P50 fair value of $15.19, maintains a middle-of-the-road standing in its industry. Investors should note this average quality tier when evaluating the certainty and potential timeline of reaching the median fair value.
What this means for investors
The Fairly Valued verdict for IART, supported by a median fair value of $15.19, implies that the stock's current price of $13.92 already largely reflects its fundamental strengths and weaknesses. The +9.1% upside to the P50 might attract some, but the average quality tier suggests that any potential appreciation comes without a clear competitive edge over its sector counterparts. While our Monte Carlo simulations provide a robust probabilistic outlook, current investors should weigh the modest upside potential against the company's average quality standing. Both downside scenarios and bull cases are part of the full probabilistic distribution. For a deeper understanding, investors can sign up for FairCurve to see the full bear/bull distribution and track IART's fair value as new fundamentals are released.
Frequently Asked Questions
Is IART overvalued or undervalued right now?
IART is currently Fairly Valued at $13.92. Our median fair value (P50) estimate for the stock is $15.19.
What is the bear case and bull case for IART?
The full Monte Carlo distribution, including specific bear case (P10) and bull case (P90) price targets, as well as the probability of upside, is available to users with a free FairCurve account. We do not provide specific dollar values for these scenarios outside of the platform.
How does FairCurve calculate IART's fair value?
FairCurve calculates IART's fair value using sophisticated Monte Carlo simulations, running thousands of forward-looking scenarios to determine a comprehensive probabilistic distribution. This methodology provides a robust and dynamic assessment of intrinsic value.
How can I track IART's fair value as it changes?
You can add IART to a free FairCurve watchlist to receive daily fair-value updates and instant re-valuation whenever new earnings or significant company fundamentals are released. This ensures you always have the most current intrinsic value estimate.